# Viridian Therapeutics, Inc.\DE (VRDN) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Viridian Therapeutics, Inc.\DE's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/VRDN/mda/fy2025/): filed 2026-02-26; accession 0001590750-26-000007 (https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/VRDN/mda/fy2024/): filed 2025-03-03; accession 0001590750-25-000004 (https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm)
- [FY 2023 MD&A](/company/VRDN/mda/fy2023/): filed 2024-02-27; accession 0001590750-24-000007 (https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm)
- [FY 2022 MD&A](/company/VRDN/mda/fy2022/): filed 2023-03-09; accession 0001590750-23-000002 (https://www.sec.gov/Archives/edgar/data/1590750/000159075023000002/vrdn-20221231.htm)
- [FY 2021 MD&A](/company/VRDN/mda/fy2021/): filed 2022-03-11; accession 0001590750-22-000004 (https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/vrdn-20211231.htm)

Back to /company/VRDN/